Real‐Life Impact of Enfortumab Vedotin or Chemotherapy in the Sequential Treatment of Advanced Urothelial Carcinoma: The <scp>ARON</scp>‐2 Retrospective Experience

Authors

Institutions

Publication Details

Journal
Cancer Medicine
Published
2025-02-01
DOI
https://doi.org/10.1002/cam4.70479
Citations
5
Primary Topic
Bladder and Urothelial Cancer Treatments
Type
article
Field-Weighted Citation Impact
10.03
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Real‐Life Impact of Enfortumab Vedotin or Chemotherapy in the Sequential Treatment of Advanced Urothelial Carcinoma: The ARON‐2 Retrospective Experience

Maria Teresa Bourlon, Halima Abahssain, Zin Myint, Sebastiano Buti et al.
5 citations
Cancer Medicine
Bladder and Urothelial Cancer Treatments
10.03
article

Real‐Life Impact of Enfortumab Vedotin or Chemotherapy in the Sequential Treatment of Advanced Urothelial Carcinoma: The ARON‐2 Retrospective Experience

Maria Teresa Bourlon, Halima Abahssain, Zin Myint, Sebastiano Buti, Camillo Porta, Matteo Santoni, Andrey Soares, Johannes Landmesser, Giandomenico Roviello, Enrique Grande, Javier Molina‐Cerrillo, Mimma Rizzo, Franco Morelli, Lorena Incorvaia, Annalisa Zeppellini, Samer Salah, Francesco Massari, Yüksel Ürün, Alexandr Poprach, Fernando Sabino Marques Monteiro, Lazar Popović, Hideki Takeshita, Shilpa Gupta, Patrizia Giannatempo, Se Hoon Park
article en
5 citations

Abstract

No abstract available for this paper.
Cancer MedicineVol. 14(4)
University of Parma (IT), Cleveland Clinic (US), University of Kentucky (US), Ankara University (TR), University of Novi Sad (RS), Masaryk University (CZ), Casa Sollievo della Sofferenza (IT), Hospital Israelita Albert Einstein (BR), Samsung Medical Center (KR), Markey Cancer Center (US), King Fahad Specialist Hospital (SA), Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda (IT), Azienda Universitaria Ospedaliera Consorziale - Policlinico Bari (IT), Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (MX), Oncology Institute of Vojvodina (RS), University Hospital Schleswig-Holstein (DE), Masaryk Memorial Cancer Institute (CZ), Azienda USL di Bologna (IT), Hospital Sírio-Libanês (BR), Institut National d'Oncologie (MA), Istituti di Ricovero e Cura a Carattere Scientifico (IT), Fondazione IRCCS Istituto Nazionale dei Tumori (IT), Social Insurance Saitama Chuo Hospital (JP), MD Anderson Cancer Center Madrid (ES), Hospital Universitario Ramón y Cajal (ES), Ospedale di Macerata, University of Florence (IT), University of Macerata (IT), University of Bari Aldo Moro (IT), Sungkyunkwan University (KR), Saitama Medical University (JP), Universidad Panamericana (MX), University of Palermo (IT), University of Lübeck (DE), University of Bologna (IT)
Openalex Percentile: Top 2%
Bladder and Urothelial Cancer Treatments
10.03
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.